Davis Robert E 4

4 · Intra-Cellular Therapies, Inc. · Filed Jan 5, 2018

Form 4

Period: 2018-01-03

SVP, Chief Scientific Officer

Transactions

Award
Stock Option (right to buy)
2018-01-03+65,164→ 65,164 total
Exercise: $15.47Exp: 2028-01-03→ Common Stock (65,164 underlying)
Award
Restricted Stock Units
2018-01-03+48,480→ 48,480 total
→ Common Stock (48,480 underlying)
Exercise/Conversion
Common Stock
2018-01-03+2,648→ 30,512 total
Sale
Common Stock
2018-01-04$15.60/sh−1,115$17,394→ 29,397 total
Exercise/Conversion
Restricted Stock Units
2018-01-03−2,648→ 5,298 total
→ Common Stock (2,648 underlying)

Footnotes (6)

[F1]Restricted stock units convert into common stock on a one-for-one basis.
[F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017. The proceeds from this sale will be used primarily to cover the reporting person's tax liability arising from the vesting of restricted stock units.
[F3]Each restricted stock unit represents a contingent right to receive one share of common stock.
[F4]On January 3, 2017, the reporting person was granted 7,946 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
[F5]On January 3, 2018, the reporting person was granted options to purchase 65,164 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
[F6]On January 3, 2018, the reporting person was granted 48,480 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Documents

1 file